Specific Biologics Raises $35 Million Series A Led By Hatteras Venture Partners For ALS Gene-Editing Therapy
· pulse2.com · popularity 20/100 · 0 similar stories today · Genetics, Genomics & Biotech (Science)
Read the original at pulse2.com →
Summary
Specific Biologics, a biotechnology company developing precision gene-editing therapies, has completed an oversubscribed $35 million Series A financing round led by Hatteras Venture Partners. Existing investors Lumira Ventures and adMare BioInnovations participated alongside new investors Genesys Capital, BDC's Life Sciences Venture Fund, DeepWork Capital, and Seido Capital. The post Specific Biologics Raises $35 Million Series A Led By Hatteras Venture Partners For ALS Gene-Editing Therapy appeared first on Pulse 2.0 .
Found in: Pulse 2.0. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 6.